C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
Provided By GlobeNewswire
Last update: Sep 13, 2024
CFT1946 Is Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities
CFT1946 Achieves Dose Proportional Pharmacokinetic Exposure; Successfully Degrades BRAF V600 Mutant Protein
Read more at globenewswire.com
